Abstract: miR-128 has been associated with cancer, particularly with leukemia. In particular, this miR has been described, together with other miRs, to allow the discrimination between AML (acute myeloid leukemia) and ALL (acute lymphoblastic leukemia). In addition, miR-128 is included in miR signatures which not only allow characterizing a particular subtype of AML but are also associated with worse clinical outcome in a subgroup of patients with high-risk molecular features of AML. Nevertheless, all the published studies are based on data from expression arrays and no functional studies have been performed. Therefore, in order to further understand the role of miR-128 in AML cells and in their response to some chemotherapy, overexpression of miR-128 was achieved with miR-mimics in an AML cell line (HL-60). This resulted in decreased cellular viability and increased sensitization to both etoposide and doxorubicin. Overexpression of miR-128 increased programmed cell death but had no effect on cell cycle profile, 1 apoptosis or autophagy, as no alterations were observed in the protein levels of PARP, pro-caspase-3, Vps34, Beclin-1 or LC3-II. In addition, miR-128 overexpression increased the levels of DNA damage, as could be concluded by an increase in the comet's tail intensity in the comet assay, an increase in the number of DNA repair foci stained with either γ-H2AX or 53BP1 proteins, and an increase in the levels of these two proteins (observed by Western blot). To the best of our knowledge, this is the first association of miR-128 with DNA damage in a leukemia context.
INTRODUCTION
The aberrant expression of microRNAs (miRs) is associated with various diseases, including cancer where they can function as oncogenes or tumor suppressor genes [1] [2] [3] [4] . miR-128 has been associated with cancer. This association was first suggested in 2005 when, through miR microarrays analysis, miR-128 expression was found downregulated in glioblastoma tissue and cell lines [5] . Later, in 2007, a study was published which discriminated acute lymphoblastic leukemia (ALL) from acute myeloid leukemia (AML) through the analysis of their miR expression signatures [6] . In this study, miR-128 was one of the four miRs that could accurately distinguish these two types of leukemias being overexpressed in ALL, when compared to AML samples [6] . miR-128 expression was later found, in a microRNA signature related to clinical outcome, to be associated "with a subgroup of patients with high-risk molecular features of AML (those who have FLT3-ITD, wild-type NPM1, or both)" [7] . Increased miR-128 expression was associated with increased risk of incomplete remission, relapse and death [7] . miR-128 (which is a brain-enriched miR) is transcribed from two different gene copies located on chromosomes 2 and 3, named miR-128-1 and miR-128-2, respectively. The resulting two miRs (both miR-128) are identical in their mature forms.
A study by Weiss and collaborators was the first to describe a direct target for miR-128 [8] . In this study, downregulation of EGFR was shown to occur through miR-128 direct interaction. In addition, this work showed that in lung cancer cell lines and also in clinical specimens, mir-128 deletion had a significant correlation with positive patient response and survival to EGFR tyrosine kinase inhibitor treatment with gefitinib [8] .
Since then, other targets for this miR have been described. In neuroblastoma cells, miR-128 was shown to target and downregulate the expression of Reelin and DCX, two "proteins involved in the migratory potential of neural cells" [9] . In addition, the oncogene/stem cell renewal factor, Bmi-1, has also been described as a target of miR-128. In fact, miR-128 was found to be downregulated in gliomas and its overexpression reduced glioma cell proliferation and selfrenewal through Bmi-1 targeting [10] . miR-128 was also shown to target E2F3a mRNA, preventing its translation and thus inhibiting the proliferation of glioma cells [11] . The low miR-128 expression may contrib-ute to glioma and glioblastoma increased proliferation by coordinately upregulating the described transcription regulators (Bmi-1 and E2F3a) as well as ARP5 (another of its described targets known to regulate cell regeneration and proliferation), resulting in uncontrolled proliferation of brain cells [12] . There are other studies that have also depicted Bmi-1 as one of the main targets of miR-128. In one of such studies, by increasing intracellular reactive oxygen species levels via inhibition of Bmi-1, miR-128 inhibited cell growth by promoting senescence in medulloblastoma cancer cells [13] . In pituitary tumor cells, miR-128 was found to be downregulated when compared to normal tissue and it was confirmed (by luciferase assay) that miR-128 targets Bmi-1, contributing to the involvement of miR-128 in the regulation of tumorigenicity and invasiveness. This regulation involved the binding of Bmi-1 to PTEN promoter, decreasing PTEN expression levels and leading to an increase in AKT activity in the pituitary tumor cells [14] .
Ectopic expression of miR-128 in breast tumour-initiating cells (BT-ICs) led to a decrease in cell viability; increase in apoptosis and in DNA damage upon further treatment with doxorubicin. In this study by Zhu et al., miR-128 directly decreased the mRNA translation not only of Bmi-1 but also of ABCC5 (multidrug resistance-associated protein 5 involved in the export of xenobiotics from the cell). The same authors also found that patients with higher expression levels of miR-128 have significantly longer overall survival, after being submitted to chemotherapy, than those with lower expression of miR-128 [15] .
Apoptosis related proteins have also been shown to be (direct or indirect) targets of this miR. miR-128 was found to bind Bax mRNA, leading to its decreased translation in human embryonic kidney cells and breast cancer cells [16, 17] , and to indirectly increase Bcl-2 expression in neuroblastoma cells [18] . miR-128 was also shown to induce apoptosis via PUMA upregulation, by interfering with SIRT1 expression in breast and colon cancer cells [19] . miR-128 has also been suggested to target the TGFβ signaling pathway [20] . Indeed, miR-128 reduced TGFβRI protein levels by binding to its mRNA 3'UTR in breast cancer cells [20] . In gliomas, miR-128 has also been shown to inhibit tumor growth and angiogenesis by directly targeting p70S6K1 (a key downstream target of mTOR pathway) and its signaling molecules (namely HIF-1α and VEGF) [21] . miR-128 was suggested to be a tumor suppressor miR that is generally found decreased in human glioma, exerting a tumor suppressive function by increasing cell cycle arrest and increasing apoptosis. miR-128 also represses gliomainitiating neural stem cells growth, enhancing neuronal differentiation by directly targeting two receptor tyrosine kinases-the epithelial growth factor receptor (EGFR) and the platelet-derived growth factor receptor-α (PDGFR-α) [22] .
In prostate, miR-128 was found overexpressed in benign epithelial cell lines when compared with invasive cancer cells. In addition, silencing miR-128 caused increased invasion of benign epithelial cells, while its overexpression reduced invasion of cancer cells [23] . miR-128 was also shown to target and downregulate the colony stimulating factor-1 (CSF-1) mRNA and protein levels in ovarian cancer cell lines which caused a reduction in cell motility and adhesion [24] .
Very recently, miR-128 was described to belong to a group of miRs which target the RET proto-oncogene in acute leukemia [25] .
Interestingly, treatment with some drugs/natural products has been shown to increase miR-128 levels. Indeed, NVP-LDE-225, a drug in early-stage clinical trials, increased miR-128 expression therefore inhibiting Bmi-1 and thus regulating stemness and cancer stem cell growth [26] . Also in glioma, miR-128 was found to be upregulated upon treatment with the ginsenoside Rh2, a component of the traditional medicinal plant ginseng, mediating a Rh2 antiproliferative effect [27] .
AML is a clonal disorder of hematopoietic stem cells. This disease is described by a rapid growth of abnormal white blood cells which concentrate in the bone marrow. The neoplastic myeloblasts are "frozen" at various stages of incomplete maturation, "with a loss in the normal hematopoietic function due to alterations in the mechanisms of self-renewal, proliferation and differentiation" [28] [29] [30] .
Several reports have associated miR-128 and leukemia [6, 7, 25, 31, 32] . These reports have shown that miR-128 belongs to a set of miRs that can distinguish between AML and ALL (acute lymphoblastic leukemia) [6, 31] . Moreover, that a particular subtype of AML with the translocation t(8;16)(p11;p13) may be characterized by a distinctive miR signature that includes miR-128 [25] or that miR-128 is part of a miR signature that is related to worse "clinical outcome in a subgroup of patients with high-risk molecular features of AML" [7] . Nevertheless, all these studies used miRNA expression arrays but none of them carried out functional studies or analysed miR-128 expression regarding therapy response, with the aim of understanding the role of miR-128 in leukemia cells. Therefore, to understand the effect of miR-128 in acute myeloid leukemia drug response, the overexpression of miR-128 in an AML cell line (HL-60) was performed with miR-mimics. In addition, the effects of this overexpression on DNA damage and drug sensitivity were analysed.
MATERIAL AND METHODS

Human Samples
A total of 13 human normal blood and 11 bone marrow AML samples were obtained from Centro Hospitalar São João, Porto, Portugal. The study was approved by the São João Hospital's ethical review board and designed according to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants. Samples were separated using Ficoll-Paque PLUS (GE Healthcare). Briefly, samples were mixed with sterile PBS, placed on FicollPaque PLUS and centrifuged for 30 min at 400g. White blood cells were harvested and washed in PBS before freezing at -80ºC. RNA was then extracted and analysed following the protocol mentioned below in "microRNA-128 expression analysis".
Cell Line
HL-60 (acute myeloid leukemia) cell line, purchased from DSMZ, was genotyped and kept in RPMI 1640 me-dium with UltraGlutamine I (Lonza) completed with 10% fetal bovine serum (FBS, PAA Laboratories) at 37ºC in an atmosphere containing 5% CO2 in humidified air. Cellular density and viability were routinely analysed with Trypan Blue exclusion assay [33] .
Transfection of HL-60 Cells with pre-miR-128
HL-60 cells (5x10 5 cells/mL) were transfected with the following pre-miRs from Life Technologies: pre-miRNA for miR-128 (miR-128) and negative control Pre-miR™ miRNA Precursor Molecules Negative Control #1 (miR-NC). For transfection, Lipofectamine™ (4 µl) and Plus™ reagents (4 µl) (Life Technologies) were used following manufacturer's instructions. All transfections were performed in serum free medium for the initial 3 h using 50 nM of pre-miRs. FBS was then added to complete final 10% concentration. Cells were further incubated or processed according to the following protocols.
Treatments with Doxorubicin and Etoposide
Following 3 h of transfection (as described above), doxorubicin (30 nM) or etoposide (200 nM) were added to the cells. The equivalent volume of the drug vehicle (DMSO) was added to control cells. Cell number and viability were determined 24 and 48 h later, with the Trypan Blue exclusion assay.
miR-128 Expression Analysis
Total RNA was extracted from human samples and from HL-60 cells (24 h following transfection of pre-miRs), using TRI Reagent ® (Life Technologies) according to the manufacturer's instructions (but replacing 1-bromo-3-chloropropane with chloroform), as previously described [34] . Quantitative real-time PCR (qPCR) was executed with the miScript SYBR Green System (Qiagen), as previously described [34] using the following primers from Qiagen: miR-128 (Hs_miR-128_1) and U6 (Hs_RNAU6B_2, as control). For each primer, standard curves were determined using serial dilutions of HL-60 cDNA. The dissociation curves obtained had a single peak. Three independent experiments were performed using duplicates and negative control reactions were included. PCRs were performed in 7500 Fast Real-Time PCR System (Applied Biosystems) and results analysed with 7500 Software v2.0.6 (Applied Biosystems).
Expression of Proteins Involved in Apoptosis, Autophagy and DNA Damage -Western Blot
Following 24 or 48 h transfection with pre-miRs, cell protein lysates were prepared, quantified and protein expression analysis was performed by Western blot, as previously described [35, 36] . The following primary antibodies were used: Beclin-1 (1:1000), LC3 (1:1000) and Vps34 
Analysis of Programmed Cell Death and Apoptosis
Programmed cell death was carried out with the TUNEL assay using the "in situ cell death detection kit" (Roche), as previously described [37] , 24 and 48 h following transfection with pre-miRs.
Cells were fixed in 4% paraformaldehyde (PFA) and transferred to slides with a cytospin. After permeabilization in ice-cold 0.1% Triton X-100 in 0.1% sodium citrate, cells were incubated with TUNEL reaction mixture (enzyme dilution 1:20). Slides were mounted in Vectashield Mounting Media with DAPI and visualized in a DM2000 fluorescence microscope (LEICA). A minimum of 300 cells per slide were counted for a semi-quantitative evaluation of cells undergoing programmed cell death. Apoptosis was quantified 48 h following transfection with pre-miRs by flow cytometry using the Annexin V-FITC/PI Kit (Bender MedSystems) as previously described [38] . Flow cytometry analysis of phosphatidylserine externalization was performed with a flow cytometer (Epics XL-MCL Coulter) and the FlowJo 7.6.5 software (Tree Star, Inc.).
Analysis of Cellular Proliferation and Cell Cycle Profile
Cellular proliferation was analysed using the BrdU incorporation assay. Briefly, 47 h following transfection with pre-miRs, cells were subjected to a pulse of BrdU (10 µM) for 1 h and then fixed in 4% PFA in PBS as previously described [39] . Cytopsins were prepared and slides incubated with: 2 M HCl for 20 min, mouse anti-BrdU (1:10, Dako) for 1 h, anti-mouse IgG-FITC (1:100, Dako) for 1 h. Slides were prepared with Vectashield Mounting Media with DAPI and cells visualized in a microscope (LEICA DM2000). A minimum of 500 cells per slide were counted (for a semiquantification).
For cell cycle profile analysis, cells were harvested and fixed (70% ethanol). Cells were afterwards resuspended in PBS with 0.1 mg/mL RNase A and 5 µg/mL propidium iodide, before analysis. The percentage of cells in the different phases of the cell cycle was quantified using the FlowJo 7.6.5 software (Tree Star, Inc.) [40] by plotting at least 10000 cells per sample.
Analysis of DNA Damage by the Alkaline Comet Assay
Cells were harvested 24 and 48 h following transfection and frozen (in 10% DMSO in FBS) at -80 ºC. After thawing, cells were washed in PBS, resuspended in 0.6% low melting point agarose and quickly poured onto slides, precoated with 1% agarose in water, with the aid of a coverslip. Slides were kept 10 min on ice in order to allow agarose to set. After removing the coverslip, cells were lysed with ice-cold lysis buffer (100mM Na2EDTA, 2.5M NaCl, 10mM Tris-HCl, pH 10.0, 1% Triton X-100) overnight, in the dark, at 4 ºC, followed by two 10 min washes in ice-cold distilled water. Slides were placed on an electrophoresis tank filled with electrophoresis buffer (10 M NaOH; 200mM Na 2 EDTA) and incubated for 20 min to allow DNA to unwind. Electrophoresis was carried out for 20 min at 23 V, 300 mA and slides were flooded with neutralisation buffer (0.4 M Tris, pH 7.5) for 20 min and then rinsed in ice-cold water for 10 min before being allowed to dry at room temperature overnight.
Slides were rehydrated with distilled water (for 30 min). They were then covered with 2.5 µg/mL of propidium iodide solution and incubated for 20 min at room temperature in the dark. Propidium iodide was rinsed with distilled water for 30 min and slides dried at 37ºC. Comets were visualized using a LEICA DM2000 fluorescent microscope and analysed using the 'Comet Assay IV v4.3' imaging system (Perceptive Instruments). A minimum of 100 cells per condition were analysed.
Expression of Proteins Involved in DNA Damage -Immunofluorescence
To visualize 53BP1 and γ -H2AX protein expression, 24 and 48 h after transfection with pre-miRs, cells were fixed in 4% PFA. After cytospin, cells were blocked for 10 min (in 50 mM of ammonium chloride in PBS) and then permeabilized for further 10 min (in ice-cold 0.2% Triton X-100 in PBS). After blocking with 2% BSA in PBS for 20 min, slides were incubated with a mouse antibody for phosphoHistone H2A.X (Ser139; 1:400 from Millipore) or a rabbit antibody for 53BP1 (1:200, from Santa Cruz Biotechnology) diluted in 2% BSA in PBS, overnight at 4ºC. Cells were then washed with 2% BSA in PBS and incubated with an appropriate secondary antibody (mouse or rabbit IgG conjugated to FITC; 1:100; Dako) for 1 h at room temperature. Slides were prepared with Vectashield Mounting Media with DAPI (Vector Laboratories) and cells visualized using a fluorescence microscope (ZEISS Axio Imager. Z1 coupled with ApoTome Imaging System microscope). Images were obtained in TIF format, decompressed with Irfanview (ver. 4.35, Irfan Skiljan) and analysed with ImageJ (version 1. 46r, http://rsbweb.nih.gov/ij/index.html), using a module written by Dr. Niklas Schultz at GMT Department, Stockholm University, Sweden [41] . The output file of this program provides the foci area, intensity and the number of foci per nucleus.
Statistical Analysis
All data was statistically analysed with the two-tailed paired Student's t-test. Data was considered statistically significant when p<0.05.
RESULTS
miR-128 Overexpression in HL-60 Cells Decreases Cellular Viability and Increases Cellular Sensitivity to Doxorubicin and Etoposide
In order to understand the effect of miR-128 in an AML cell line, HL-60 cells were transiently transfected with miR-128 or with a control miR (miR-NC). Upon 24 h of transfection, a clear overexpression of miR-128 was detected, by qPCR, confirming the success of the transfection. Indeed, an average of 1480 times more miR-128 was observed in the miR-128 transfected cells in relation to cells transfected with miR-NC (Fig. 1A) .
The effect of miR-128 overexpression on HL-60 cells was then assessed by analysing viable cell number. It was possible to observe that miR-128 overexpression decreased HL-60 viable cell number to 92.0%, 84.3% and 81.0%, at 12 h, 24 h and 48 h following transfection respectively, when comparing to Blank cells (untreated cells in exponential growth). Moreover, this decrease was found to be statistically significant at 24 h and 48 h but not at 12 h following transfection (Fig. 1B) . In addition, a very small reduction in viable cell number was observed in the miR-NC transfected cells but this decrease was not statistically significant.
To confirm if miR-128 overexpression affected the HL-60 cellular response to drugs, cells were treated with two chemotherapeutic drugs (doxorubicin and etoposide) following transfection with miR-128 or miR-NC, and the viable cell number was assessed. As previously observed, miR-128 overexpression was found to decrease the viable cell number per se (white columns, Fig. 1C) . In addition, treatment with the drug vehicle (DMSO) did not affect viable cell number (grey columns, Fig. 1C) . Interestingly, miR-128 overexpression sensitized HL-60 cells to doxorubicin, since a reduction in viable cell number was observed in cells transfected with miR-128 (when compared with miR-NC transfected cells). This sensitization was statistically significant at 24 h (striped columns, Fig. 1C) . miR-128 overexpression also sensitized HL-60 cells to etoposide as a reduction in viable cell number was also observed in cells transfected with miR-128 (when compared with miR-NC transfected cells). This sensitization was statistically significant at both 24 h and 48 h (checkered columns, Fig. 1C ).
miR-128 Overexpression Does not Affect Cell Cycle, Cellular Proliferation, Apoptosis Nor the Expression of Apoptosis-related and Autophagy-related Proteins
Since miR-128 overexpression was found to significantly decrease HL-60 viable cell number and to sensitize these cells to the effect of the conventional chemotherapeutic drugs, etoposide and doxorubicin, we investigated some of the possible mechanisms involved. Hence, the effects of miR-128 overexpression on cell cycle profile, cellular proliferation, programmed cell death, apoptosis and autophagy induction were studied. Cells overexpressing miR-128 showed no alterations in cell cycle profile, analysed by PI staining and flow cytometry, both 24 h and 48 h following transfection ( Fig. 2A) . The levels of BrdU incorporation in cells overexpressing miR-128 were also not altered, in relation to blank or miR-NC transfected cells (data not shown). On the other hand, when analysing programmed cell death (with TUNEL assay), an increase in the number of cells labeled positive was observed following miR-128 overexpression, both at 24 h and 48 h. This increase was statistically significant at 48 h following transfection (p<0.05), when comparing to cells transfected with miR-NC. Indeed, cells transfected with miR-128 presented 8.2% TUNEL-labeled cells, whereas cells transfected with miR-NC only presented 3.4% of TUNEL-labeled cells (Fig. 2B) . Taking these results into account and since TUNEL may not only label apoptotic cells, a specific assay for apoptosis was carried out by analysing Annexin-V/PI staining by flow cytometry. Surprisingly, when analysing the levels of apoptosis using this methodology, no major differences between cells transfected with miR-NC and cells overexpressing miR-128 were observed (Fig. 2C) . In addition, the expression levels of some apoptotic related proteins, namely procaspase-3 and PARP were also analysed by Western Blot and no significant alterations in their levels were observed between cells transfected with miR-NC and miR-128 (Fig. 2D) . Therefore, since autophagy has also been described as being involved in cell death, the expression of proteins related to autophagy was analysed by Western Blot. Nevertheless, the levels of Vps34, Beclin-1 and LC3-II did not present any alterations between miR-NC and miR-128 transfected cells (Fig. 2E) .
miR-128 Overexpression Increases DNA Damage
In order to understand what was causing the decrease in viable cell number and increase in TUNEL labeling of miR-128 transfected cells, the effect of miR-128 overexpression in DNA damage induction was analysed by the comet assay and immunofluorescence for γ -H2AX and 53BP1. By analysing the results from the comet assay, it was observed that the percentage of Comet Tail DNA (which is indicative of the % of DNA damage in that cell/comet) was higher in cells transfected with miR-128, than in cells transfected with miR-NC. This increase was from 3.6% in miR-NC transfected cells to 8.1% in miR-128 transfected cells and was statistically significant (p<0.05) (Fig. 3A) . To further confirm that miR-128 overexpression induced DNA damage, DNA repair foci formation was analysed by immunofluorescence using antibodies for γ -H2AX and 53BP1. Moreover, the levels of both these proteins were analysed by Western blot. Results from the total number of γ-H2AX foci in cells (analysed by immunofluorescence) indicated that miR-128 transfected cells presented a higher number of these foci per cell than cells transfected with miR-NC. This was observed both at 24 h and at 48 h following transfection, with this increase being statistically significant at 24 h for γ-H2AX (p<0.05) (Fig. 3B) . Accordingly, the levels of γ-H2AX were also increased (although not statistically significantly) in the Western blot analysis 24 h after miR-128 transfection (Fig. 3C) . Regarding 53BP1, cells overexpressing miR-128 were also found to present a higher number of foci per cell, when compared with miR-NC transfected cells. This was also observed both at 24 h and 48 h, being statistically significant at 48 h (p<0.05) (Fig. 3D) . This increase was further confirmed by observing a statistically significant increase in 53BP1 protein expression in miR-128 overexpressing cells (Fig. 3E) . 
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miR-128 Expression in AML Patient Samples
Expression of miR-128 was analysed by qPCR in samples from PBMCs of 13 healthy donors and from bone marrow of 11 AML patients ( Table 1) . Although the differences were not statistically significant (p value = 0,157), the expression levels of miR-128 in the AML samples were 1.87 times higher than in healthy donors.
DISCUSSION
Over the last decade the interest on miRs has grown tremendously, with thousands of miRs being identified in various organisms [42] . miRs were shown to be crucial in regulating gene expression, mostly by post-transcriptional regulation, and controlling disease processes. Particularly, miRs have been described as being involved in cancer. Indeed, some miRs may act as 'oncogenes', whereas others act as 'tumour suppressor genes' [43] .
Although miR-128 has been described as a brainenriched miR [44] its expression has been shown to be altered in various types of cancer such as breast [17] or lung cancer [8] . Indeed, miR-128 has been shown to be involved in the regulation of important cell oncogenic processes such as cell proliferation [11] , invasion [9] or apoptosis [19] . Moreover, miR-128 has been shown to be altered in leukemia [6, 7, 25, 31] . In this context, to date, there are no functional studies on miR-128 in leukemia cells. The present study adds knowledge to this area.
In addition, drug resistance, which is frequently associated with poor prognosis in cancer [45, 46] , has also been shown to be indirectly controlled by the expression of some miRs, as these molecules may regulate several cellular mechanisms that are pivotal for cancer drug resistance [47, 48] . Curiously, the involvement of miR-128 in drug resistance has been described in several studies, although some of them present contradictory results. On the one hand some reports point out miR-128 expression as being related to sensitization to drugs [15] , while on the other hand other studies associate miR-128 expression with increased drug resistance [17, 49] . In order to clarify this issue, in this study the effect of miR-128 on cellular sensitization to two chemotherapeutic drugs (doxorubicin and etoposide) was studied. Results from this work showed that overexpressing miR-128 per se decreased the viable cell number of HL-60 cells. This was in agreement with some of the previously published studies in different cancer cell models [11, 13, 21, 50] . In addition, in this study, miR-128 overexpression was also shown to sensitize cells to two chemotherapeutic drugs -doxorubicin and etoposide. This was in agreement with other study in which miR-128 overexpression sensitized breast tumor cells to doxorubicin [15] . Nonetheless, miR-128 overexpression did 53BP1 protein levels * not cause a synergistic or additive effect with these drugs, as often happens when concomitantly targeting various mechanisms in the cells. Nevertheless, some other studies have shown the opposite effect in breast and lung cancer cells [17, 49] . In addition to this, the proliferation levels and cell cycle profile of HL-60 cells overexpressing miR-128 showed no alterations, although alterations in both had been shown by others, for brain tumor cells and for human embryonic kidney cells [11, 12, 16] . These contradictory results may be explained by the different genetic background and tissue origin of the cell lines used in the present study, compared to others.
In this study, the fact that the percentage of TUNEL positive cells (suggesting programmed cell death) was increased in cells overexpressing miR-128 prompted us to further analyse the cellular levels of apoptosis. Curiously, when comparing miR-NC with miR-128 transfected cells, no significant alterations were observed, neither in the Annexin-V/PI staining nor in the expression of the apoptosis related proteins procaspase-3 and PARP (the former being a protein known to be involved in the first steps of apoptosis and the latter a recognized target of apoptosis induction). Nevertheless, the TUNEL assay has previously been described as not being specific for apoptosis, as it may also label nonapoptotic cells [51, 52] . In fact, there are studies showing that cells undergoing autophagy activation can also be labeled by TUNEL [53, 54] . This led us to analyse the expression of autophagy related proteins upon miR-128 overexpression. Nonetheless, no alteration in autophagic protein levels was observed. We then hypothesized that the increase in TUNEL labelling in the miR-128 overexpressing cells could be due to DNA damage. Intrinsic DNA damage may arise from errors taking place during DNA replication, from endogenous reactive oxygen species (ROS) produced from normal metabolic byproducts or from extrinsic genotoxic stresses (including ultraviolet light, ionizing radiation, chemo-and radiotherapeutic agents) [55, 56] . miR-128 has been predicted and shown to target proteins involved in DNA damage response [57] [58] [59] and interestingly, miR-128 has been recently shown to increase intracellular ROS levels [13] . The present study shows that miR-128 overexpressing leukemia cells had increased DNA damage. Indeed, results from the alkaline comet assay (a method that quantifies DNA damage by the increasing content of DNA in the tail of the comets) showed a clear increase in DNA tail intensity in miR-128 overexpressing cells, as was already seen by others in breast tumor cells [15] . Confirmation of DNA damage induction was possible by monitoring γ -H2AX and 53BP1 protein expression, whose foci are evidence of persistent DNA double strand breaks (DSBs) [60] . The observed increase in the number of foci of γ -H2AX and 53BP1 indicated an increase in DNA DSBs, which might justify the increased sensitivity to doxorubicin and etoposide of miR-128 overexpressing cells.
Other miRs associated to DNA damage have been already described to interfere with chemosensitivity. For example, when miR-18a was overexpressed in colorectal cancer cells, those cells were less capable of recovering from etoposide-induced DNA damage (when compared to miR-NC transfected cells), suggesting a possibly reduced DNA DSBs repair mechanism [61] . Indeed, it is known that miR18a reduces ataxia telangiectasia mutated protein, a central molecule in promoting repair of DNA DSBs [61] .
In the context of this model of acute promyelocytic leukemia, miR-128 may lead to DNA damage (possibly by affecting the expression of proteins involved in DNA repair, since as mentioned above, miR-128 has been shown to target proteins involved in DNA damage response [57] [58] [59] ), that accumulates without prompt repair causing increased sensitivity to DNA damaging drugs such as etoposide and doxorubicin. Results from cell lines led us to analyse the levels of miR-128 in AML samples. All samples were 'de novo' AMLs, therefore none of the patients had previous treatment for AML. The samples analysed were very heterogeneous as patients presented different karyotypes and mutational status and therefore different leukemia associated risk ( Table 1) . A slight increase in the expression of miR-128 was found in AML bone marrow samples, when compared to PBMCs from healthy donors. Even though the differences were not statistically significant, this suggests that these patients may have an increased DNA damage. However, definitive conclusions cannot be taken from these results, as the sample size was very small and the samples analysed were very heterogeneous. Nevertheless, further studies on the levels of DNA damage on these patients might help explaining the role of miR-128 in leukemia. In addition, it would be very interesting to correlate miR-128 levels in these patients to response to DNA damage agents.
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